Comparison of incidence/occurrence of cardiovascular events between ponatinib vs bosutinib among patients with at least one prior line of tyrosine kinase inhibitors in chronic myeloid leukemia in a community setting in the United States.

Abstract

INTRODUCTION:

In this real-world study, the incidence of cardiovascular events (CV) including major adverse cardiac events (MACE), arterial occlusive events (AOE), and venous occlusive events (VOE) was evaluated in chronic myeloid leukemia (CML) patients treated with ponatinib or bosutinib in a US commercial database population.

MATERIALS AND METHODS:

CML patients aged ≥18 years with use of 1 or 2 prior tyrosine kinase inhibitors prescribed bosutinib or ponatinib were selected from the IBM® MarketScan® Research database. Cox proportional hazard model analyses were conducted to examine any difference in CV event risk.

RESULTS:

Ponatinib and bosutinib was associated with similar incidence and risk of CV events, including MACEs (HR: 1.02; 95% CI: 0.35, 3.01), AOEs (HR: 0.90; 95% CI: 0.43, 1.85) and VOEs (HR: 0.92; 95% CI: 0.44, 1.94).

CONCLUSION:

Treatment with ponatinib or bosutinib was not associated with significant differences in the incidence of CV events in CML patients.

• Authors: Moshe Levy, Lin Xie, Yuexi Wang, Frank Neumann, Shouryadeep Srivastava, Daniel Naranjo, Jing Xu, Qisu Zhang, Mehul Dalal
• Journal: Cancer treatment and research communications (Cancer Treat Res Commun) Vol. 28 Pg. 100424 ( 2021) ISSN: 2468-2942 [Electronic] England
• PMID: 34198039 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2021. Published by Elsevier Ltd.

Chemical References

• Aniline Compounds
• Imidazoles
• Nitriles
• Protein Kinase Inhibitors
• Pyridazines
• Quinolines
• ponatinib
• bosutinib

Topics

• Aniline Compounds (adverse effects)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects)
• Cardiovascular Diseases (chemically induced, pathology)
• Female
• Humans
• Imidazoles (adverse effects)
• Incidence
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)
• Male
• Middle Aged
• Nitriles (adverse effects)
• Protein Kinase Inhibitors (adverse effects)
• Pyridazines (adverse effects)
• Quinolines (adverse effects)
• Risk Factors
• Treatment Outcome
• United States